Ophthotech Corporation (NASDAQ:OPHT) belonging to the Medical sector which declined -5.55% and closed its last trading session at $43.57.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/3/2016. Currently, the stock has a 1 Year Price Target of $93.73.
The consensus recommendation, according to Zacks Investment research, is 1.06. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.06 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.06 and 1.06 respectively.
Ophthotech Corporation on 6/30/2016 reported its EPS as $-0.85 with the analysts projecting the EPS of the stock as $-1.05. The company beat the analyst EPS Estimate with the difference of $0.2. This shows a surprise factor of 19%.
Many analysts have provided their estimated foresights on Ophthotech Corporation Earnings, with 10 analysts believing the company would generate an Average Estimate of $-1.64. Whereas they predicted High and Low Earnings Estimate as $-1.44 and $-1.82 respectively. While in the same Quarter Previous year, the Actual EPS was $-1.14.
Analysts are also projecting an Average Revenue Estimate for Ophthotech Corporation as $6.2 Million in the Current Quarter. This estimate is provided by 7 analysts. The High Revenue estimate is predicted as 9.1 Million, while the Low Revenue Estimate prediction stands at 3.8 Million. The company’s last year sales total was 3.45 Million.
The Company got Upgrade by JP Morgan on 2-Jun-16 from Neutral to Overweight.
Insider Trades for Ophthotech Corporation show that the latest trade was made on 31 Aug 2016 where Guyer (David R), the Chief Executive Officer completed a transaction type “Sell” in which 24060 shares were traded at a price of $52.58.
15 Insider Sales transactions were made totaling 236137 shares traded.
11 analysts projected Price Targets for Ophthotech Corporation. The analysts believe that the company stock price could grow as high as $200. The Low Price target projection by analysts is $45 and the Mean Price Target is $93.73.
Ophthotech Corporation (NASDAQ:OPHT) has the market capitalization of $1.82 Billion. The company rocked its 52-Week High of $80 on Dec 30, 2015 and touched its 52-Week Low of $38.06 on Oct 6, 2015. The stock has Return on Assets (ROA) of -34 percent. Return on Equity (ROE) stands at -296.6% and Return on Investment (ROI) of -178.2 percent.
The stock is currently showing YTD performance of -44.52 Percent. The company has Beta Value of 0 and ATR value of 2.68. The Weekly and Monthly Volatility stands at 5.29% and 4.18%.
Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.